New MASH drug OPK-88006 enters early human testing
NCT ID NCT07512427
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called OPK-88006 in 30 people, first in healthy volunteers and then in those with MASH (a serious liver condition). The goal is to check safety, how the drug moves through the body, and early signs of liver improvement. Results will help decide if larger studies are warranted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
OPKO study site
RECRUITINGMiami, Florida, 33143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a once-daily pill help children with fatty liver disease?
- Fatty liver disease: a new biobank aims to unlock the secrets of a silent epidemic
- New pill for fatty liver disease enters first human tests
- New gut implant aims to tackle diabetes and obesity without surgery
- New models aim to predict liver disease in HIV patients
- Could a stomach tuck reverse fatty liver?